Modifications in the papillary thyroid cancer gene profile over the last 15 years - PubMed (original) (raw)
Multicenter Study
. 2012 Sep;97(9):E1758-65.
doi: 10.1210/jc.2012-1269. Epub 2012 Jun 28.
Laura Fugazzola, Efisio Puxeddu, Francesco Frasca, David Viola, Marina Muzza, Sonia Moretti, Maria Luisa Nicolosi, Carlotta Giani, Valentina Cirello, Nicola Avenia, Stefania Rossi, Paolo Vitti, Aldo Pinchera, Rossella Elisei
Affiliations
- PMID: 22745248
- DOI: 10.1210/jc.2012-1269
Multicenter Study
Modifications in the papillary thyroid cancer gene profile over the last 15 years
Cristina Romei et al. J Clin Endocrinol Metab. 2012 Sep.
Abstract
Background: Evidence for an increased prevalence of BRAF(V600E) mutations has been documented in recent decades. The aim of this study was to evaluate the prevalence of both RET/PTC rearrangements and BRAF(V600E) mutations in an Italian cohort of papillary thyroid carcinoma (PTC) patients followed at the Endocrine Units of Pisa, Milano, and Perugia from 1996-2010.
Patients and methods: In total, 401 PTC patients were examined and grouped according to the time of surgery: group 1, 1996-2000; group 2, 2001-2005; and group 3, 2006-2010. Patients were analyzed for clinical, pathological, and molecular features. In parallel, the molecular characteristics of 459 PTC from Sicily were studied.
Results: The genetic profiles of the three groups were significantly different (P < 0.0001). In particular, the frequency of RET/PTC rearrangements decreased from 1996-2010, occurring in 33 of 100 (33%) of the patients in group 1, 26 of 148 (17%) in group 2, and 15 of 153 (9.8%) in group 3. The incidence of BRAF(V600E) mutations increased over the same period, from 28% in group 1 (28 of 100) to 48.9% in group 2 (73 of 148) and 58.1% in group 3 (89 of 153). A consistent increase in BRAF(V600E) prevalence was observed in the Sicilian group (P < 0.0001). Moreover, a statistically significant increase in the mean age at diagnosis and decrease in tumor size over the study period was observed.
Conclusion: The genetic profile of PTC changed over the last 15 yr, with a significant decrease in the prevalence of RET/PTC rearrangements and an increase in BRAF(V600E) mutations. In addition, the mean age at diagnosis increased and tumor size decreased over the study period.
Similar articles
- [Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].
Rumiantsev PO, Zaletaev DV, Vasil'ev EV, Saenko VA, Il'in AA, Rumiantseva UV, Abrosimov AIu, Medvedev VS. Rumiantsev PO, et al. Vopr Onkol. 2006;52(2):145-9. Vopr Onkol. 2006. PMID: 17195637 Russian. - Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
Pizzolanti G, Russo L, Richiusa P, Bronte V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M, Bommarito A, Citarrella R, Lo Coco R, Cabibi D, Lo Coco A, Frasca F, Gulotta G, Latteri MA, Modica G, Galluzzo A, Giordano C. Pizzolanti G, et al. Thyroid. 2007 Nov;17(11):1109-15. doi: 10.1089/thy.2007.0008. Thyroid. 2007. PMID: 17727338 - Radiation induced thyroid cancer: fundamental and applied aspects.
Tronko M, Bogdanova T, Voskoboynyk L, Zurnadzhy L, Shpak V, Gulak L. Tronko M, et al. Exp Oncol. 2010 Sep;32(3):200-4. Exp Oncol. 2010. PMID: 21403618 - Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Quiros RM, et al. Cancer. 2005 Jun 1;103(11):2261-8. doi: 10.1002/cncr.21073. Cancer. 2005. PMID: 15880523 Review. - RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.
Ciampi R, Nikiforov YE. Ciampi R, et al. Endocrinology. 2007 Mar;148(3):936-41. doi: 10.1210/en.2006-0921. Epub 2006 Aug 31. Endocrinology. 2007. PMID: 16946010 Review.
Cited by
- Thyroid cancer and endocrine disruptive chemicals: a case-control study on per-fluoroalkyl substances and other persistent organic pollutants.
Cirello V, Lugaresi M, Moneta C, Dufour P, Manzo A, Carbone E, Colombo C, Fugazzola L, Charlier C, Pirard C. Cirello V, et al. Eur Thyroid J. 2024 May 20;13(3):e230192. doi: 10.1530/ETJ-23-0192. Print 2024 Jun 1. Eur Thyroid J. 2024. PMID: 38657654 Free PMC article. - Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids.
Lasolle H, Schiavo A, Tourneur A, Gillotay P, de Faria da Fonseca B, Ceolin L, Monestier O, Aganahi B, Chomette L, Kizys MML, Haenebalcke L, Pieters T, Goossens S, Haigh J, Detours V, Maia ALS, Costagliola S, Romitti M. Lasolle H, et al. Oncogene. 2024 Jan;43(3):155-170. doi: 10.1038/s41388-023-02889-y. Epub 2023 Nov 20. Oncogene. 2024. PMID: 37985676 Free PMC article. - Long-Term Changes in the Mortality Rates of Thyroid Cancer in Korea: Analysis of Korean National Data from 1985 to 2020.
Choi YM, Kim MJ, Lee J, Kwak MK, Jeon MJ, Kim TY, Hong EG, Kim WB, Kim WG. Choi YM, et al. Endocrinol Metab (Seoul). 2023 Oct;38(5):588-595. doi: 10.3803/EnM.2023.1723. Epub 2023 Sep 8. Endocrinol Metab (Seoul). 2023. PMID: 37679950 Free PMC article. - Uncovering the Uncommon: An 81-Year-Old Woman With Elevated Carcinoembryonic Antigen (CEA) but Normal Calcitonin Levels Diagnosed With Medullary Thyroid Carcinoma.
Ukrani J, Barnes M, Ashraf A, Haggerty G, Dacosta N. Ukrani J, et al. Cureus. 2023 Jun 12;15(6):e40290. doi: 10.7759/cureus.40290. eCollection 2023 Jun. Cureus. 2023. PMID: 37448402 Free PMC article. - Incidence, Recurrence and Mortality Among Filipinos With Differentiated Thyroid Cancer: A Systematic Review.
San Juan MD, Paz-Pacheco E. San Juan MD, et al. J ASEAN Fed Endocr Soc. 2023;38(1):100-107. doi: 10.15605/jafes.038.01.14. Epub 2023 Mar 2. J ASEAN Fed Endocr Soc. 2023. PMID: 37252408 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials